Likes Subject
MRNA PFE BNTX COURT FILING WON BY ABUS mick 01/02/22 1:14 PM
cash cow my friend $abus mick 05/29/23 6:21 PM
ABUS Arbutus Biopharma Corporation mick 05/29/23 6:21 PM
ABUS Arbutus Biopharma Corporation mick 05/29/23 6:21 PM
ABUS 1Q23 results—3/31/23 cash=$178.5M: DewDiligence 05/04/23 11:00 AM
ABUS Arbutus Biopharma Corporation mick 04/30/23 7:03 PM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical mick 04/18/23 4:07 PM
With a median price-to-sales (or "P/S") ratio of mick 04/18/23 4:06 PM
ABUS Arbutus Biopharma Corporation mick 04/15/23 2:42 PM
rare form / https://investorshub.advfn.com/Arbutus-Biopharma-Corporation-17838#: mick 04/15/23 2:42 PM
A U.S. appeals court affirmed a decision to
Bullish
Bullish
mick 04/14/23 1:10 PM
A U.S. appeals court affirmed a decision to mick 04/12/23 12:46 PM
ABUS Benzinga • 4 minutes ago mick 04/12/23 12:43 PM
Connecting da dots finally/ $ABUS infringement suit on mick 04/11/23 11:26 PM
it started wit gov't labs , in canada
Bullish
Bullish
mick 04/04/23 10:15 PM
why should the govt being the one who Paullee 04/04/23 9:27 PM
dis is connection to the last two messages
Bullish
Bullish
mick 04/04/23 4:12 PM
background and Pfizer statement, updates share movement) $ABUS
Bullish
Bullish
mick 04/04/23 4:11 PM
dis could be $20 or more worth to
Bullish
Bullish
mick 04/04/23 4:10 PM
ABUS/Genevant* sue PFE/BNTX re LNP technology_in_COVID_vaccine: DewDiligence 04/04/23 10:02 AM
ABUS presents preclinical data on COVID antiviral, AB-343 DewDiligence 03/14/23 4:36 PM
ABUS 4Q22 results: DewDiligence 03/02/23 9:08 AM
ABUS Arbutus Biopharma Corporation mick 02/26/23 7:18 PM
$ABUS patent infringement MRNA /\ patent infringement mick 02/16/23 10:32 AM
I AM SURPRISED NO DIVY TO SHAREHOLDERS ALL
Bullish
Bullish
mick 02/05/23 6:58 PM
THANK YOU, $ABUS mick 02/05/23 6:57 PM
ABUS Arbutus Biopharma Corporation mick 02/05/23 6:56 PM
ABUS provides 2023 roadmap: DewDiligence 01/05/23 10:22 AM
Can someone remind me what we are waiting too simple 12/28/22 7:31 AM
ABUS Arbutus Biopharma Corporation mick 12/18/22 6:45 PM
Maybe. Slojab 12/08/22 11:46 AM
Hell Yea, here we go!!! Little Run 11/02/22 7:04 PM
Order Document: 32 Paullee 11/02/22 6:09 PM
ABUS discontinues AB-836 for HBV due_to safety problem: DewDiligence 11/01/22 7:13 PM
ABUS Arbutus Biopharma Corporation mick 10/23/22 2:29 PM
ABUS Arbutus Biopharma Corporation mick 08/31/22 8:12 PM
Arbutus Biopharma (ABUS) Receives a Buy from H.C. Wainwright mick 08/30/22 1:31 PM
https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-ABUS/stock-news/88944 mick 08/30/22 11:57 AM
abus bout Arbutus mick 08/30/22 11:55 AM
abus About HBV mick 08/30/22 11:54 AM
abus About AB-729 mick 08/30/22 11:54 AM
abus AB-729 is currently in multiple Phase 2a mick 08/30/22 11:54 AM
abus “We are pleased to be granted this mick 08/30/22 11:53 AM
ABUS GlobeNewswire • 4 hours ago mick 08/30/22 11:49 AM
ABUS 2Q22 CC transcript: DewDiligence 08/05/22 10:51 AM
ABUS 2Q22 results—6/30/22 cash=$200.6M—(down from $222M @3/31/22): DewDiligence 08/04/22 3:53 PM
HBV trial of AB-729 with ASMB’s VBR terminated DewDiligence 07/20/22 5:11 PM
Chardan Capital Reaffirms Their Buy Rating on Arbutus mick 07/17/22 6:21 PM
ABUS Arbutus Biopharma Corporation mick 07/17/22 6:21 PM
ABUS’ AB-836 HBV capsid inhibitor shows_safety_signal_in_phase-1b_trial—see slid DewDiligence 06/27/22 3:58 PM
ABUS EASL CC slides: DewDiligence 06/27/22 3:35 PM
Likes Subject

mick
05/29/23 6:21 PM
mick
05/29/23 6:21 PM
mick
05/29/23 6:21 PM
DewDiligence
05/04/23 11:00 AM
mick
04/30/23 7:03 PM
mick
04/15/23 2:42 PM
mick
04/12/23 12:43 PM
mick
04/04/23 10:15 PM
Paullee
04/04/23 9:27 PM
mick
04/04/23 4:10 PM
DewDiligence
03/02/23 9:08 AM
mick
02/26/23 7:18 PM
mick
02/05/23 6:57 PM
mick
02/05/23 6:56 PM
DewDiligence
01/05/23 10:22 AM
too simple
12/28/22 7:31 AM
mick
12/18/22 6:45 PM
Slojab
12/08/22 11:46 AM
Little Run
11/02/22 7:04 PM
Paullee
11/02/22 6:09 PM
mick
10/23/22 2:29 PM
mick
08/31/22 8:12 PM
mick
08/30/22 11:55 AM
mick
08/30/22 11:54 AM
mick
08/30/22 11:54 AM
mick
08/30/22 11:49 AM
DewDiligence
08/05/22 10:51 AM
DewDiligence
07/20/22 5:11 PM
mick
07/17/22 6:21 PM
DewDiligence
06/27/22 3:35 PM

Arbutus Biopharma Corporation (ABUS)

Followers
125
Posters
372
Posts (Today)
0
Posts (Total)
6659
Created
05/13/10
Type
Free
Moderators mick


UPDATE; 10-12-2021
$abus uptrend wedge, inverted head & shoulder too.

[-chart]charts.stocktwits.com/production/original_385257980.jpg[/chart]




UPDATE; 10-09-2021
$ABUS COURTESY OF


$ABUS HEARING VIDEO
Twitter Spaces re Moderna v Arbutus Patent Appeal Oral Argument
460 viewsOct 7, 2021
https://www.youtube.com/watch?v=3duSGLOygX0&ab_channel=DanRavicher

UPDATE;
Reviewing 10-06-2021 $ABUS FACTS: & $ABUS WOW FOR INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!

ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS


1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant

AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!

MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE



UPDATE;09-27-2021
ABUS and Roivant launched Genevant as a joint venture in 2018.

Roivant will begin trading as ROIV this Friday, assuming its' merger with the MAAC SPAC is approved Tuesday.

Since Genevant is 60% owned by Roivant and 40% owned by ABUS, it sits under the Roivant banner as one of the Roivant Vants.
There were no shares spun off because Genevant remains private.


From https://www.dcatvci.org/6162-emerging-pharma-roivant-sciences-on-the-rise

"Vivek Ramaswamy is leading a family of companies that include multiple wholly owned or majority-owned subsidiaries (so-called “Vants”),
each focused on a different disease area or technology that supports the process of developing and commercializing medicines.
The company employs a “hub and spoke” model for research and development, whereby each biopharmaceutical subsidiary functions as
an independent entity (“spoke”) using shared resources from the parent (“hub”)
and the technology-based subsidiaries focused on different aspects of data science."



https://www.globenewswire.com/en/news-release/2018/04/11/1468874/14025/en/Arbutus-and-Roivant-Launch-Genevant-Sciences-with-Industry-Leading-Platform-to-Develop-Broad-Range-of-RNA-Therapeutics-for-Genetic-Diseases.html

"Under the terms of the agreement, Roivant will contribute $37.5 million in transaction-related seed capital for Genevant.
Roivant is committed to financially support Genevant in its aim to advance 5 to 10 product candidates into the clinic by 2020.
Arbutus will retain all rights to the LNP and conjugate delivery platforms for HBV,
and will be entitled to a tiered royalty from Genevant on future sales of products enabled by those delivery platforms.
Arbutus will also retain the entirety of its royalty entitlement on the commercialization of Alnylam’s patisiran,
which could see regulatory approval as early as the second half of 2018."



In April 2018, Arbutus and Roivant Sciences Ltd. (its largest shareholder) launched the spinoff Genevant Sciences Ltd. (“Genevant”).
Under the terms of that deal, Arbutus licensed exclusive rights to its non-HBV LNP technology to Genevant (including the ‘069 patent)
and took a minority 40% common equity share in Genevant, compared to Roivant’s 60% share.




'COMPANY ORGANIZATION CHART' 09-26-2021
$ABUS [-chart]charts.stocktwits.com/production/original_383829800.png[/chart]




UPDATE; 09-10-2021
$ABUS HIGHLIGHTS
NO DEBT
Insider Own 19.15%
Inst Own 31.70%
Inst Trans 11.15%
Shs Outstand 96.87M
Shs Float 80.17M
Target Price 5.90 [WITHOUT INFRINGEMENT PATENT
PENDING]
52W Range 2.35 - 5.87
https://finviz.com/quote.ashx?t=ABUS
 
 
UPDATE; 09-10-2021

Arbutus rises 15% on apparent patent fight win with Moderna

Sep. 09, 2021 4:20 PM ETABUS, BNTX...By: Jonathan M BlockSA News Editor
https://seekingalpha.com/news/3738496-arbutus-rises-15-on-apparent-patent-fight-win-with-moderna
  • Shares of Arbutus Biopharma (NASDAQ:ABUS) closed up 15% amid speculation it has won a patent fight against Moderna (NASDAQ:MRNA).
    Arbutus may receive a new patent and as a result, may be eligible for royalties from Moderna from sales of its COVID-19 vaccine.
    The U.S. Patent and Trademark Office website shows that Arbutus was granted a notice of allowance on Sept. 2 for a patent covering novel lipid formulations for nucleic acid delivery.
    In the past, Moderna has unsuccessfully challenged similar patents.
    Moderna is appealing the validity of those patents with a hearing before a federal appellate court on Oct. 7
    An article published in Forbes last month highlighted that scientific papers and regulatory documents indicate that both Moderna's vaccine and
    Pfizer (NYSE:PFE)/BioNTech's (NASDAQ:BNTX) use a delivery system that is quite similar to what Ian McLachlan, who worked at Tekmira, which later changed its name to Arbutus, created.

 



http://www.arbutusbio.com/

http://www.arbutusbio.com/about-arbutus/overview.php
https://investor.arbutusbio.com/scientific-advisory-board
http://www.arbutusbio.com/about-hbv/hbv-science.php
PARTNERS
http://www.arbutusbio.com/portfolio/genevant.php
http://www.arbutusbio.com/partners/partnerships.php
http://www.arbutusbio.com/partners/hbv-partnerships.php
https://investor.arbutusbio.com/press-releases



UPDATE; 04-27-2021
#2 $ABUS FACTS: & $ABUS WOW FOR DIS INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!

ABUS 
1) May 4th Appeals Briefs due in MRNA vs ABUS  069. Oral next. ABUS asked for extension.ABUS 


1) May 4th Appeals Briefs due in MRNA vs ABUS  069. Oral next. ABUS asked for extension.
2) May 5th.  HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020 
4) NO major PR since mid March,  PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020. 
7) Announced 
$75M
Offering last meeting. ATM.  At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.  
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.  
24 million shares at $7.  Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year  "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!!  AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant

AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!

MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses: 
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE







11-17-2020
Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS).

https://www.smarteranalyst.com/new-blurbs/chardan-capital-remains-a-buy-on-arbutus-biopharma-abus/?mod=mw_quote_news

11-17-2020
$ABUS [B.Riley Financial Keeps a Buy Rating on Arbutus Biopharma (ABUS).]

https://www.smarteranalyst.com/new-blurbs/b-riley-financial-keeps-a-buy-rating-on-arbutus-biopharma-abus/?mod=mw_quote_news



$ABUS #2 RATING $8 JMP Securities Initiates Coverage on Arbutus Biopharma (NASDAQ:ABUS)
SHARE
MONDAY, JULY 27, 2020 | MARKETBEAT

https://www.marketbeat.com/instant-alerts/nasdaq-abus-a-buy-or-sell-right-now/


 
Arbutus  T$MRNA &$ABUSGOOD STUFF Sunday, 26 July 2020
Moderna Must Move Quickly To Buy Arbutus
Arbutus Biopharma Corporation (ABUS)
Current Price: $4.96
Target Price: $15.00
Upside Potential: 202%
Market Cap: $342 million
Shares Outstanding: 69 million
Float: 38 million
https://value-trades.blogspot.com/


http://www
http://www.arbutusbio.com/about-arbutus/overview.php
http://www.arbutusbio.com/
http://www.arbutusbio.com/about-hbv/hbv-science.php
http://www.arbutusbio.com/about-hbv/blumberg.php
http://www.arbutusbio.com/portfolio/ab-729-galnac-rnai.php
http://www.arbutusbio.com/portfolio/capsid-inhibitors.php
http://www.arbutusbio.com/portfolio/hbv-rna-destabilizer.php $MRNA &$ABUSGOOD STUFF Sunday, 26 July 2020
 
https://value-trades.blogspot.com/

PARTNER;
http://www.arbutusbio.com/portfolio/genevant.php
http://www.arbutusbio.com/portfolio/gritstone.php
http://www.arbutusbio.com/portfolio/patrisiran.php
http://www.arbutusbio.com/portfolio/marqibo.php

PARTERS;
http://www.arbutusbio.com/partners/hbv-partnerships.php
http://www.arbutusbio.com/partners/partnering-licensing-opportunities.php


 
All Navigate to...- Any - Releases

[-chart]finviz.com/chart.ashx?t=ABUS&ty=c&ta=1&p=d&s=l[/chart]




https://finviz.com/quote.ashx?t=ABUS&ty=c&ta=1&p=d   [SHARES HAVE INCREASED SOME SINCE DIS WAS DONE 04-27-2021]
Shs Outstand 67.68M
Shs Float 44.46M
 
Short Float 1.72%
Debt/Eq   NO DEBT -
 
Inst Own 38.60%
 
Cash/sh 0.98
Sales Q/Q 114.30%
EPS Q/Q 46.60%
52W Range 0.82 - 6.48


$ABUS FIVE YR.





https://www.otcmarkets.com/stock/ABUS/disclosure

https://www.otcmarkets.com/stock/ABUS/news

https://www.otcmarkets.com/stock/ABUS/security

https://www.otcmarkets.com/stock/ABUS/profile

https://www.otcmarkets.com/stock/ABUS/quote

https://www.otcmarkets.com/stock/ABUS/overview








 

PER  IHUB  MGMT 

02-07-2021
DISCLAIMER:  ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
 
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION 
AUTHORS MAY HAVE BUYS OR SELLS  WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.

ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Any



 







 
Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post